Government’s investment of 1.3 billion to boost API manufacturing in India

Following the news that the Indian Government has approved US$ 1.3 billion (approximately Rs 1000 crore) healthcare package to boost the domestic manufacturing of active pharmaceutical ingredients (API), according to Global data report. Prashant Khadayate, pharma analyst at GlobalData, offers his view, “The package, which is part of a turnaround strategy to reduce India’s dependence on China, will help boost the capabilities of domestic API manufacturers. The timing of the announcement was crucial as Indian pharma companies are facing potential supply disruptions due to the Covid-19 outbreak. Indian pharma manufacturers depend heavily for their supply of fine chemicals and drug intermediates on China.” According to him, as part of the strategy, three API manufacturing parks will be set up in different parts of the country to further help in setting up API manufacturing units, and incentive scheme will be implemented for the production of government identified 53 API’s by the manufacturers. China is a key supplier of both Chemical API and chemical intermediates for the global pharmaceutical industry. The Covid-19 outbreak has the potential to…

Choose your subscription to read more